HIGHLIGHTS
- who: Breast cancer and collaborators from the Department of, University of Oxford, Churchill Hospital, LE Oxford, UK have published the Article: Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic, in the Journal: (JOURNAL)
- what: ERu03b1 is more widely expressed than ERu03b2 and while ERu03b2 is thought to have antiproliferative actions, it is believed ERu03b1 activation leads to proliferation in breast cancers and is the main focus of the review article. Using in_vivo patient-derived xenograft mouse models, this study showed that metformin, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.